THIS PRESS RELEASE WAS ORIGINALLY RELEASED IN SWEDISH FOR THE SWEDISH MARKET AND HAS LATER BEEN TRANLSATED TO ENGLISH FOR GENERAL AWARENESS ON THE GLOBAL MARKET.
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.
SenzaGen AB (“SenzaGen” or “the Company”) announces a public offering of the Company’s shares and applies for listing of these shares on Nasdaq First North in Stockholm (“the Offer”). The Company has therefore prepared a prospectus (“the Prospectus”) which has today been approved by and registered with Finansinspektionen, the Swedish Financial Supervisory Authority. The Prospectus is now available on the Company’s website, www.senzagen.com/investors, and elsewhere.
SenzaGen has decided to offer shares in the Company to the general public in Sweden and Denmark (with certain restrictions) as well as to institutional investors in Sweden and abroad, and is therefore applying for listing on Nasdaq First North in Stockholm. The purpose of the Offer is to finance the expansion of the Company’s sales organization and its existing product portfolio with new tests based on the existing GARD platform.
The Offer and the subsequent listing on Nasdaq First North will give the Company access to capital markets, create liquidity in the Company’s shares, and also bring new shareholders to SenzaGen, thereby strengthening the Company’s development. SenzaGen’s listing is also expected to have a positive effect on the Company’s relationships with partners and potential customers.
The offer in brief
- The Offer consists of up to 4,645,000 shares.
- The subscription price has been set at 19.40 SEK per share.
- The Offer amounts to a total of approximately SEK 90 million.
- The portion of the Offer relating to the general public in Denmark is limited to shares totalling less than 1 million euros or equivalent amount in SEK.
- The total Offer corresponds to a valuation of SenzaGen of approximately SEK 210 million (pre-money).
- The application period for the public will last from 4thSeptember to 12th September 2017.
- The settlement date is September 19th
- Estimated first day of trading, provided that Nasdaq Stockholm AB approves the Company’s application, is September 21st
The application form will be available on SenzaGen’s website, www.senzagen.com/investors, Vator Securities website, www.vatorsecurities.se and Nordnet’s website, www.nordnet.se/emissioner, throughout the application period.
The majority of existing as well as new institutional and qualified investors have already undertaken to subscribe for shares to a total of approximately SEK 75 million, equivalent to 83 percent of the Offer. Among these are Ålandsbanken Funds Ltd, Leif GW Persson, Jörgen Book, formerly with global market responsibility for strategy and pricing of respiratory products at AstraZeneca, and Per Lindberg, former global technology analyst and now an investor.
For full details of the Offer, please refer to the Prospectus (available in Swedish only). The Prospectus has today been approved by and registered with the Swedish Financial Supervisory Authority (Finansinspektionen) and is available on SenzaGen’s website, www.senzagen.com/investors, Vator Securities website, www.vatorsec.se and will be available on the Finansinspektionen website, www.fi.se, within a few days.
Certified Adviser and Issuing agent
Vator Securities are the Company’s financial adviser and Baker McKenzie is the Company’s legal adviser. The issuing agent for the transaction is Nordnet Bank.
For further information, please refer to the Prospectus, which has been approved by and registered with the Swedish Financial Supervisory Authority with regard to the share issue, prior to the planned listing on Nasdaq First North.
For further information, please visit the Company’s website, www.senzagen.com or contact: Anki Malmborg Hager, CEO of SenzaGen AB, email: email@example.com, telephone: +46 76 828 48 22.
GARD™ is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability.
This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD™ tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com
This announcement is not and does not form a part of any offer for sale of securities.
Copies of this announcement are not being made and may not be distributed or sent into the United States, Australia, Canada, Japan, New Zealand, South Africa, Hong Kong, Singapore or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.
An offering of the securities referred to in this announcement is made by means of the prospectus referred to herein. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.
Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe,” “expect,” “anticipate,” “intends,” “estimate,” “will,” “may,” “continue,” “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.